Media, News
Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF). The company has received US FDA clearance to…
Media, News
Prescient Therapeutics welcomes US FDA allowance of Investigational New Drug application for PTX-100 Phase 2 clinical trial
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is trading higher after receiving a green light from the US Food and Drug Administration (FDA) to proceed with its Phase 2 clinical…
Media, News
Prescient Therapeutics appoints experienced pharmaceuticals executive James McDonnell as CEO
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), which is developing a pipeline of targeted, personalised therapies for cancer, has tapped James McDonnell to lead the…
Media, News
Miles Prince Q&A Update
Reach Markets recently interviewed Professor H. Miles Prince AM – the Principal Investigator of our PTX-100 program – regarding its phase 1b trial and the…
Article, News
Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research
A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at up to 16.4 cents per share, using a Sum…
Article, News
Prescient Therapeutics: PTX-100 Phase 2 coming soon
Prescient Therapeutics update report 2024 08 29
Media, News
Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr Gavin Shepherd as an independent…
Media, News
Prescient Therapeutics: Current Developments in Cancer Treatment
Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms of cancer, with a specific focus on blood cancers that…
Article, Media, News
Prescient Therapeutics PTX-100 shows promising results in Phase 1b study
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead of a presentation of the…
Article, News
Prescient Therapeutics to present PTX-100 results at T-Cell Lymphoma Forum in California
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has been invited to present PTX-100 Phase 1b results at the 15th Annual T-Cell Lymphoma Forum (TCLF) to be…